Hands On Webinar | What's New in the 2026 Standards of Care? | Recording-Hands On Webinar | What's New in the 2026 Standards of Care?

Video Transcription

Video Summary

The webinar reviewed key updates in the ADA 2026 Standards of Care, highlighting practical outpatient changes across diagnosis, prevention, management, technology, and complication screening.<br /><br />Speakers emphasized population health foundations: team-based, integrated care; quality improvement methods; and addressing health equity and care gaps. In diagnosis and classification, updates included clearer guidance on islet autoantibody testing and screening for presymptomatic type 1 diabetes, with TrialNet data noting particularly high progression risk when IA-2 autoantibodies are present, prompting closer monitoring.<br /><br />New content addresses hyperglycemia and diabetes triggered by cancer therapies (e.g., glucocorticoids, immune checkpoint inhibitors, PI3K and mTOR inhibitors), recommending routine glucose monitoring and, in some situations, preventive metformin. Diabetes prevention continues to prioritize lifestyle and weight loss; metformin remains the only drug specifically recommended for type 2 diabetes prevention, while teplizumab is noted for delaying onset of symptomatic type 1 in stage 2 disease.<br /><br />Comprehensive evaluation updates included simplified screening for metabolic-associated liver disease using a streamlined FIB-4 approach and treatment guidance by disease stage. DSMES and nutrition guidance reinforced whole-food patterns and minimizing ultra-processed foods; new emphasis included vaping/cannabis screening, fasting guidance, and sleep assessment.<br /><br />Glycemic goals now incorporate CGM-based targets aligned with A1C goals, plus strengthened hypoglycemia prevention (including oral glucose in first-aid kits). Technology guidance expanded CGM and automated insulin delivery recommendations, including fewer payer barriers (e.g., no C-peptide requirements) and workplace/school accommodations. Cardiovascular updates tightened blood pressure goals for high-risk individuals, and kidney guidance reinforced SGLT2 inhibitor use down to eGFR 20 and added finerenone criteria. Older adult care added geriatric screening tools and “red flags” to prompt treatment simplification.

Keywords

ADA 2026 Standards of Care

outpatient diabetes management updates

islet autoantibody testing and TrialNet

presymptomatic type 1 diabetes screening

cancer therapy–induced hyperglycemia

metformin for type 2 diabetes prevention

teplizumab stage 2 type 1 diabetes delay

CGM targets and automated insulin delivery

SGLT2 inhibitors eGFR 20 and finerenone

health equity and population health quality improvement